mog35 55 peptide Peptide - Mog35 55sequence Peptides Understanding the Role of MOG (35-55) Peptide in Neurological Research

Myelin oligodendrocyte glycoprotein The MOG (35-55) peptide is a critical tool in the scientific community, particularly for researchers investigating autoimmune diseases affecting the central nervous system, most notably multiple sclerosis (MS)Myelin Oligodendrocyte Glycoprotein (MOG 35-55), 25 mg. This specific peptide fragment, derived from the myelin oligodendrocyte glycoprotein (MOG), plays a significant role in inducing experimental autoimmune encephalomyelitis (EAE), a widely used animal model that mimics many aspects of human MS. Understanding the characteristics and applications of the MOG 35-55 peptide is crucial for advancing our knowledge of demyelinating diseases and developing potential therapeutic strategies.

Myelin oligodendrocyte glycoprotein (MOG) itself is a minor component of the central nervous system (CNS) myelin sheath, essential for its proper function and integrity. The MOG (35-55) fragment, specifically the sequence MEVGWYRSPFSRVVHLYRNGK, has been identified as an immunodominant epitope. This means it is highly recognized by the immune system, triggering robust T and B cell responses. When administered to susceptible animal models, such as mice and rats, this peptide can induce autoantibody production and relapsing-remitting neurological disease characterized by extensive plaque-like demyelination.2024年5月31日—OM-MOG35-55suppresses antigen-specific T cell responses associated with autoimmune demyelination. Based on these results, we developed different types of ... This induction of EAE provides researchers with a controllable system to study the complex mechanisms underlying demyelination and inflammation in the brain and spinal cord.

The MOG (35-55) peptide is a valuable resource for exploring the processes involved in autoimmune diseases. Its ability to reliably induce EAE allows scientists to investigate the role of specific immune cells, such as T cells, and the signaling pathways involved in the autoimmune attack on myelin. For instance, studies have shown that intravenous administration of MOG35-55 Peptide can inhibit EAE by suppressing the IL-17/STAT4 signaling pathway, highlighting potential therapeutic targets. The MOG 35-55 peptide is instrumental in various research applications, including T cell assays, where its high purity is essential for obtaining reproducible results.Myelin oligodendrocyte glycoprotein (MOG)peptide35-55is one of the targets of self-reactive T cell responses, leading to acute and later chronic autoimmune ...

Furthermore, research has delved into variations of this peptide. Citrullinated human and murine MOG35-55 have been shown to display distinct immunogenic properties, suggesting that post-translational modifications can influence the autoimmune response. The MOG (35-55) peptide is available in various forms, including trifluoroacetate salt, and is often supplied in quantities such as 1 mg or 25 mg, catering to different research needs. For instance, the MOG (35-55) (mouse, rat) (trifluoroacetate salt) is a common reagent. The MOG (35-55) (human) variant is also available for studies focusing on human-specific immune responses.

The scientific literature frequently refers to this peptide in various contexts. The MOG (35-55), mouse, rat designation indicates its use in both species.Explore high-purityMOG 35–55 peptidefrom peptides&elephants — immunodominant epitope in multiple sclerosis and EAE models, ideal for T cell assays. Researchers often investigate the MOG35-55 induced EAE and the specific amount of peptide needed to achieve a reliable disease model. The MOG (35-55) peptide antigen is a cornerstone for understanding the pathogenesis of MS.MOG (35-55) TFA (Myelin Oligodendrocyte Glycoprotein ... The MOG (35-55) - CNS myelin peptide for neuroscience underscores its importance in the broader field of neuroscience research.

It is important to note that products containing the MOG (35-55) peptide are chemical reagents intended for research use only and are not for human use. This distinction is crucial as these peptides are used to *induce* disease models, not for therapeutic purposes in individuals. The development of therapeutic vaccines or immunomodulatory treatments for MS, such as those based on OM-MOG35-55, is an ongoing area of research that leverages the understanding gained from studying the MOG (35-55) peptide.

In summary, the MOG (35-55) peptide is an indispensable tool for understanding the immunopathology of demyelinating diseases. Its ability to reliably induce EAE in animal models provides invaluable insights into the mechanisms of multiple sclerosis and related neurological conditions. Continued research utilizing this peptide, alongside investigations into its various forms and immunomodulatory effects, holds significant promise for the future of neurological disease research and the development of effective treatments2017年9月26日—MOG35-55induced EAE: amount ofpeptideneeded? Hi there. Has anyone done a titration curve looking at the amount of MOGpeptideused to ....